Skip to main content

Advertisement

SpringerLink
Log in

SSTR2 Expression in Olfactory Neuroblastoma: Clinical and Therapeutic Implications

  • Original Paper
  • Published:
Head and Neck Pathology Aims and scope Submit manuscript

Abstract

Somatostatin receptor 2 (SSTR2) expression has previously been documented in olfactory neuroblastoma (ONB). Here, we fully characterize SSTR2 expression in ONB and correlate staining results with clinicopathologic parameters including Hyams grade. We also assess SSTR2 immunohistochemistry expression in various histologic mimics of ONB to assess its diagnostic functionality. 78 ONBs (51 primary biopsies/excisions and 27 recurrences/metastases) from 58 patients were stained for SSTR2. H-scores based on intensity (0–3 +) and percentage of tumor cells staining were assigned to all cases. 51 histologic mimics were stained and scored in an identical fashion. 77/78 (99%) ONB cases demonstrated SSTR2 staining (mean H-score: 189, range: 0–290). There were no significant differences in staining between primary tumors and recurrences/metastases (mean H-score: 185 vs 198). Primary low-grade ONB had somewhat stronger staining than high-grade tumors (mean H-score: 200 vs 174). SSTR2 expression had no prognostic value when considering disease-free or disease-specific survival. SSTR2 staining is significantly higher in ONB than its histologic mimics (mean H-score: 189 vs 12.9, p < 0.001) suggesting a potential use of the marker in diagnosis of ONB. In conclusion, SSTR2 is consistently expressed in ONB suggesting a role for somatostatin-analog based imaging and therapy in this disease. More generally, SSTR2 may be another marker of neuroendocrine differentiation in ONB.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Patel YC, Greenwood M, Kent G, et al. Multiple gene transcripts of the somatostatin receptor SSTR2: tissue selective distribution and cAMP regulation. Biochem Biophys Res Commun. 1993;192(1):288–94.

    Article  CAS  Google Scholar 

  2. The Human Protein Atlas [internet]. Human Protein Somatostatin Receptor 2; SSTR2. https://www.proteinatlas.org/ENSG00000180616-SSTR2/tissue. Accessed 24 Sept 2020

  3. Kulaksiz H, Eissele R, Rossler D, et al. Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies. Gut. 2002;50(1):52–60.

    Article  CAS  Google Scholar 

  4. Volante M, Brizzi MP, Faggiano A, et al. Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol. 2007;20(11):1172–82.

    Article  CAS  Google Scholar 

  5. Schmid HA, Lambertini C, van Vugt HH, et al. Monoclonal antibodies against the human somatostatin receptor subtypes 1–5: development and immunohistochemical application in neuroendocrine tumors. Neuroendocrinology. 2012;95(3):232–47.

    Article  CAS  Google Scholar 

  6. Gonzalez B, Vargas G, Ramirez C, et al. Cytoplasmic expression of SSTR2 and 5 by immunohistochemistry and by RT/PCR is not associated with the pharmacological response to octreotide. Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion. 2014;61(10):523–30.

    Article  Google Scholar 

  7. Diakatou E, Alexandraki KI, Tsolakis AV, et al. Somatostatin and dopamine receptor expression in neuroendocrine neoplasms: correlation of immunohistochemical findings with somatostatin receptor scintigraphy visual scores. Clin Endocrinol. 2015;83(3):420–8.

    Article  CAS  Google Scholar 

  8. Hankus J, Tomaszewska R. Neuroendocrine neoplasms and somatostatin receptor subtypes expression. Nucl Med Rev Cent East Eur. 2016;19(2):111–7.

    Article  Google Scholar 

  9. Remes SM, Leijon HL, Vesterinen TJ, et al. Immunohistochemical expression of somatostatin receptor subtypes in a panel of neuroendocrine neoplasias. J Histochem Cytochem. 2019;67(10):735–43.

    Article  CAS  Google Scholar 

  10. Chiti A, van Graafeiland BJ, Savelli G, et al. Imaging of neuroendocrine gastro-entero-pancreatic tumours using radiolabelled somatostatin analogues. Ital J Gastroenterol Hepatol. 1999;31(Suppl 2):S190-194.

    PubMed  Google Scholar 

  11. Fanti S, Farsad M, Battista G, et al. Somatostatin receptor scintigraphy for bronchial carcinoid follow-up. Clin Nucl Med. 2003;28(7):548–52.

    Article  Google Scholar 

  12. Bustillo A, Telischi F, Weed D, et al. Octreotide scintigraphy in the head and neck. Laryngoscope. 2004;114(3):434–40.

    Article  CAS  Google Scholar 

  13. Savelli G, Lucignani G, Seregni E, et al. Feasibility of somatostatin receptor scintigraphy in the detection of occult primary gastro-entero-pancreatic (GEP) neuroendocrine tumours. Nucl Med Commun. 2004;25(5):445–9.

    Article  Google Scholar 

  14. Kwekkeboom DJ, Kam BL, van Essen M, et al. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer. 2010;17(1):R53-73.

    Article  CAS  Google Scholar 

  15. Waldmann CM, Stuparu AD, van Dam RM, et al. The search for an alternative to (68)Ga-DOTA-TATE in neuroendocrine tumor theranostics: current state of (18)F-labeled somatostatin analog Ddevelopment. Theranostics. 2019;9(5):1336–47.

    Article  CAS  Google Scholar 

  16. Wang L, Tang K, Zhang Q, et al. Somatostatin receptor-based molecular imaging and therapy for neuroendocrine tumors. BioMed Res Int. 2013. https://doi.org/10.1155/2013/102819.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Schneider JR, Shatzkes DR, Scharf SC, et al. Neuroradiological and neuropathological changes after 177Lu-Octreotate peptide receptor radionuclide therapy of refractory esthesioneuroblastoma. Op Neurosurg. 2018;15(6):100–9.

    Google Scholar 

  18. Zeng M, Cui Y, Wu C. Expression of SSTR2 and P-STAT3 in human olfactory neuroblastoma. J Clin Otorhinolaryngol Head Neck Surg. 2010;24(15):690–2.

    Google Scholar 

  19. Czapiewski P, Kunc M, Gorczyński A, et al. Frequent expression of somatostatin receptor 2a in olfactory neuroblastomas: a new and distinctive feature. Hum Pathol. 2018;79:144–50.

    Article  CAS  Google Scholar 

  20. Ramsay HA, Kairemo KJ, Jekunen AP. Somatostatin receptor imaging of olfactory neuroblastoma. J Laryngol Otol. 1996;110(12):1161–3.

    Article  CAS  Google Scholar 

  21. Chiti A, Fanti S, Savelli G, et al. Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours. Eur J Nucl Med. 1998;25(10):1396–403.

    Article  CAS  Google Scholar 

  22. García Vicente A, García Del Castillo E, Soriano Castrejón A, et al. Olfactory esthesioneuroblastoma: scintigraphic expression of somatostatin receptors. Revista Espanola de Medicina Nuclear. 1999;18(5):367–70.

    PubMed  Google Scholar 

  23. Freeman SR, Mitra S, Malik TH, et al. Expression of somatostatin receptors in arginine vasopressin hormone-secreting olfactory neuroblastoma–report of two cases. Rhinology. 2005;43(1):61–5.

    CAS  PubMed  Google Scholar 

  24. Rostomily RC, Elias M, Deng M, et al. Clinical utility of somatostatin receptor scintigraphic imaging (octreoscan) in esthesioneuroblastoma: a case study and survey of somatostatin receptor subtype expression. Head Neck. 2006;28(4):305–12.

    Article  Google Scholar 

  25. Savelli G, Bartolomei M, Bignardi M. Somatostatin receptors imaging and therapy in a patient affected by esthesioneuroblastoma with meningeal metastases. A classic example of theranostic approach. J Neuro-oncol. 2016;127(3):617–9.

    Article  Google Scholar 

  26. Makis W, McCann K, McEwan AJ. Esthesioneuroblastoma (olfactory neuroblastoma) treated with 111In-octreotide and 177Lu-DOTATATE PRRT. Clin Nucl Med. 2015;40(4):317–21.

    Article  Google Scholar 

  27. Sabongi JG, Gonçalves MC, Alves CD, et al. Lutetium 177-DOTA-TATE therapy for esthesioneuroblastoma: a case report. Exp Ther Med. 2016;12(5):3078–82.

    Article  Google Scholar 

  28. Kamel Hasan O, Ravi Kumar AS, Kong G, et al. Efficacy of peptide receptor radionuclide therapy for esthesioneuroblastoma. J Nucl Med. 2020;61(9):1326–30.

    Article  Google Scholar 

  29. Mardekian SK, Snyderman CH, Pollack AZ, et al. The value of Hyams grade in an endoscopically treated cohort of olfactory neuroblastoma. Mod Pathol. 2017;31(S2):328A.

    Google Scholar 

  30. Ma H, Lu Y, Marchbanks PA, et al. Quantitative measures of estrogen receptor expression in relation to breast cancer-specific mortality risk among white women and black women. Breast Cancer Res. 2013;15(5):R90.

    Article  Google Scholar 

  31. Berger L, Luc R. L’esthésioneuroépithéliome olfactif. Bull Assoc Franc P L’etude du Cancer. 1924;13:410–21.

    Google Scholar 

  32. Wooff JC, Weinreb I, Perez-Ordonez B, et al. Calretinin staining facilitates differentiation of olfactory neuroblastoma from other small round blue cell tumors in the sinonasal tract. Am J Surg Pathol. 2011;35(12):1786–93.

    Article  Google Scholar 

  33. Tao L, Chen Y, Shi X, et al. Expression of potential therapeutic target SSTR2a in primary and metastatic non-keratinizing nasopharyngeal carcinoma. Virchows Arch. 2020;477(4):573–9.

    Article  CAS  Google Scholar 

Download references

Funding

No funding obtained.

Author information

Authors and Affiliations

  1. Department of Pathology and Laboratory Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

    Vincent Cracolici, Simion Chiosea, Aatur D. Singhi & Raja R. Seethala

  2. Department of Otolaryngology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

    Eric W. Wang, Simion Chiosea & Raja R. Seethala

  3. Department of Neurosurgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

    Paul A. Gardner & Carl Snyderman

  4. Department of Pathology and Laboratory Medicine, Thomas Jefferson University Hospital, Philadelphia, PA, USA

    Stacey M. Gargano

  5. 9500 Euclid Avenue, L25, Cleveland, OH, USA

    Vincent Cracolici

Authors
  1. Vincent Cracolici
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eric W. Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paul A. Gardner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Carl Snyderman
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Stacey M. Gargano
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Simion Chiosea
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Aatur D. Singhi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Raja R. Seethala
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors listed made significant contributions to the study in concept and design.

Corresponding author

Correspondence to Vincent Cracolici.

Ethics declarations

Conflict of interest

The authors declare no conflicts of interest relevant to this study.

Consent to publication

All authors consent to publication in the present form.

Ethical approval

This research study was conducted retrospectively from data gathered for clinical purposes. This study was and approved by the University of Pittsburgh IRB (PRO14080496). Consent is waived due to the retrospective nature of the study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 13 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cracolici, V., Wang, E.W., Gardner, P.A. et al. SSTR2 Expression in Olfactory Neuroblastoma: Clinical and Therapeutic Implications. Head and Neck Pathol 15, 1185–1191 (2021). https://doi.org/10.1007/s12105-021-01329-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12105-021-01329-1

Keywords

Search

Navigation